Biohaven Gains Experimental Drugs From Two New Pacts

New Haven, Conn.-based Biohaven Pharmaceutical has struck a global licensing deal with Bristol Myers Squibb (BMS) to develop and market taldefgrobep alfa, an investigational therapy for treating neuromuscular diseases.

Biohaven said it plans to launch a phase 3 study this year to evaluate the drug candidate as a treatment for spinal muscular atrophy. Financial terms of the deal were not disclosed.

Biohaven also announced plans to acquire neurology drug developer Channel Biosciences, a Knopp Biosciences subsidiary, for an estimated $100 million. Under the deal, Biohaven will gain access to Channel’s lead candidate BHV-7000, an anti-seizure medication for treatment of epilepsy.

Biohaven plans to launch a clinical trial evaluating BHV-7000 for treating epilepsy this year.